Rubitecan
Rubitecan
Rubitecan (pronounced: roo-BI-te-kan) is a chemotherapeutic agent used in the treatment of cancer. It is an oral topoisomerase inhibitor, specifically inhibiting topoisomerase I, which is essential for DNA replication.
Etymology
The name "Rubitecan" is derived from its chemical structure, which is a derivative of camptothecin, a quinoline alkaloid isolated from the Chinese tree Camptotheca acuminata. The "Rubi-" prefix refers to the modifications made to the basic camptothecin structure to improve its bioavailability and therapeutic index.
Usage
Rubitecan is primarily used in the treatment of pancreatic cancer, although it has also been investigated for use in other types of cancer, including ovarian cancer and small cell lung cancer. It is administered orally, which offers advantages in terms of patient comfort and convenience compared to intravenous chemotherapy.
Side Effects
Like all chemotherapeutic agents, Rubitecan can cause a range of side effects. These can include nausea, vomiting, diarrhea, and myelosuppression, which can lead to anemia, neutropenia, and thrombocytopenia.
Related Terms
External links
- Medical encyclopedia article on Rubitecan
- Wikipedia's article - Rubitecan
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski